With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Twelve hospitals across India will be part of the network which will support the trial in India
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Clinical studies are expected to start in Q2 2023.
Subscribe To Our Newsletter & Stay Updated
